209 related articles for article (PubMed ID: 26918603)
1. Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer.
Dwivedi SK; Mustafi SB; Mangala LS; Jiang D; Pradeep S; Rodriguez-Aguayo C; Ling H; Ivan C; Mukherjee P; Calin GA; Lopez-Berestein G; Sood AK; Bhattacharya R
Oncotarget; 2016 Mar; 7(12):15093-104. PubMed ID: 26918603
[TBL] [Abstract][Full Text] [Related]
2. Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer.
Yang D; Sun Y; Hu L; Zheng H; Ji P; Pecot CV; Zhao Y; Reynolds S; Cheng H; Rupaimoole R; Cogdell D; Nykter M; Broaddus R; Rodriguez-Aguayo C; Lopez-Berestein G; Liu J; Shmulevich I; Sood AK; Chen K; Zhang W
Cancer Cell; 2013 Feb; 23(2):186-99. PubMed ID: 23410973
[TBL] [Abstract][Full Text] [Related]
3. LncRNA PTAR promotes EMT and invasion-metastasis in serous ovarian cancer by competitively binding miR-101-3p to regulate ZEB1 expression.
Liang H; Yu T; Han Y; Jiang H; Wang C; You T; Zhao X; Shan H; Yang R; Yang L; Shan H; Gu Y
Mol Cancer; 2018 Aug; 17(1):119. PubMed ID: 30098599
[TBL] [Abstract][Full Text] [Related]
4. Systematic analyses reveal long non-coding RNA (PTAF)-mediated promotion of EMT and invasion-metastasis in serous ovarian cancer.
Liang H; Zhao X; Wang C; Sun J; Chen Y; Wang G; Fang L; Yang R; Yu M; Gu Y; Shan H
Mol Cancer; 2018 Jun; 17(1):96. PubMed ID: 29929545
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-302 represses epithelial-mesenchymal transition and cisplatin resistance by regulating ATAD2 in ovarian carcinoma.
Ge T; Liu T; Guo L; Chen Z; Lou G
Exp Cell Res; 2020 Nov; 396(1):112241. PubMed ID: 32835657
[TBL] [Abstract][Full Text] [Related]
6. Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers.
Liu G; Yang D; Rupaimoole R; Pecot CV; Sun Y; Mangala LS; Li X; Ji P; Cogdell D; Hu L; Wang Y; Rodriguez-Aguayo C; Lopez-Berestein G; Shmulevich I; De Cecco L; Chen K; Mezzanzanica D; Xue F; Sood AK; Zhang W
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25995442
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-150-5p promotes cell motility by inhibiting c-Myb-mediated Slug suppression and is a prognostic biomarker for recurrent ovarian cancer.
Tung CH; Kuo LW; Huang MF; Wu YY; Tsai YT; Wu JE; Hsu KF; Chen YL; Hong TM
Oncogene; 2020 Jan; 39(4):862-876. PubMed ID: 31570789
[TBL] [Abstract][Full Text] [Related]
8. IL-6R/STAT3/miR-204 feedback loop contributes to cisplatin resistance of epithelial ovarian cancer cells.
Zhu X; Shen H; Yin X; Long L; Chen X; Feng F; Liu Y; Zhao P; Xu Y; Li M; Xu W; Li Y
Oncotarget; 2017 Jun; 8(24):39154-39166. PubMed ID: 28388577
[TBL] [Abstract][Full Text] [Related]
9. Novel role of lncRNA CHRF in cisplatin resistance of ovarian cancer is mediated by miR-10b induced EMT and STAT3 signaling.
Tan WX; Sun G; Shangguan MY; Gui Z; Bao Y; Li YF; Jia ZH
Sci Rep; 2020 Sep; 10(1):14768. PubMed ID: 32901049
[TBL] [Abstract][Full Text] [Related]
10. Systematic analysis reveals a lncRNA-mRNA co-expression network associated with platinum resistance in high-grade serous ovarian cancer.
Fang L; Wang H; Li P
Invest New Drugs; 2018 Apr; 36(2):187-194. PubMed ID: 29082457
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-625-3p improved proliferation and involved chemotherapy resistance via targeting PTEN in high grade ovarian serous carcinoma.
Zhong L; Liu X; Wang L; Liu Y; Zhang D; Zhao Y
J Ovarian Res; 2022 Jan; 15(1):7. PubMed ID: 35027053
[TBL] [Abstract][Full Text] [Related]
12. The clinical significance and biological function of lncRNA SOCAR in serous ovarian carcinoma.
Guo Q; Wang L; Zhu L; Lu X; Song Y; Sun J; Wu Z; Shi J; Wang Z; Zhou X
Gene; 2019 Sep; 713():143969. PubMed ID: 31299360
[TBL] [Abstract][Full Text] [Related]
13. Exosome-transmitted miR-128-3p increase chemosensitivity of oxaliplatin-resistant colorectal cancer.
Liu T; Zhang X; Du L; Wang Y; Liu X; Tian H; Wang L; Li P; Zhao Y; Duan W; Xie Y; Sun Z; Wang C
Mol Cancer; 2019 Mar; 18(1):43. PubMed ID: 30890168
[TBL] [Abstract][Full Text] [Related]
14. Long non-coding RNA ZFAS1 interacts with miR-150-5p to regulate Sp1 expression and ovarian cancer cell malignancy.
Xia B; Hou Y; Chen H; Yang S; Liu T; Lin M; Lou G
Oncotarget; 2017 Mar; 8(12):19534-19546. PubMed ID: 28099946
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of Foxo3 and TRIM31 by miR-551b in side population promotes cell proliferation, invasion, and drug resistance of ovarian cancer.
Wei Z; Liu Y; Wang Y; Zhang Y; Luo Q; Man X; Wei F; Yu X
Med Oncol; 2016 Nov; 33(11):126. PubMed ID: 27743201
[TBL] [Abstract][Full Text] [Related]
16. miRNA-301b-3p accelerates migration and invasion of high-grade ovarian serous tumor via targeting CPEB3/EGFR axis.
Liu F; Zhang G; Lv S; Wen X; Liu P
J Cell Biochem; 2019 Aug; 120(8):12618-12627. PubMed ID: 30834603
[TBL] [Abstract][Full Text] [Related]
17. DYRK2 regulates epithelial-mesenchymal-transition and chemosensitivity through Snail degradation in ovarian serous adenocarcinoma.
Yamaguchi N; Mimoto R; Yanaihara N; Imawari Y; Hirooka S; Okamoto A; Yoshida K
Tumour Biol; 2015 Aug; 36(8):5913-23. PubMed ID: 25712377
[TBL] [Abstract][Full Text] [Related]
18. MiR-149-3p promotes the cisplatin resistance and EMT in ovarian cancer through downregulating TIMP2 and CDKN1A.
Wang J; Liu L
J Ovarian Res; 2021 Nov; 14(1):165. PubMed ID: 34798882
[TBL] [Abstract][Full Text] [Related]
19. MiR-338-3p Enhances Ovarian Cancer Cell Sensitivity to Cisplatin by Downregulating WNT2B.
Niu Q; Liu Z; Gao J; Wang Q
Yonsei Med J; 2019 Dec; 60(12):1146-1156. PubMed ID: 31769245
[TBL] [Abstract][Full Text] [Related]
20. Extracellular microRNA profiling for prognostic prediction in patients with high-grade serous ovarian carcinoma.
Yoshida K; Yokoi A; Matsuzaki J; Kato T; Ochiya T; Kajiyama H; Yamamoto Y
Cancer Sci; 2021 Dec; 112(12):4977-4986. PubMed ID: 34618992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
